Exploring GPRC5D as an Important Target for Multiple Myeloma

Publication
Article
ONCOLOGY® CompanionONCOLOGY® Companion, Volume 38, Supplement 9
Volume 38
Issue 9
Pages: 3

Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.

Meet the experts

Meet the experts

A recent Training Academy highlighted the use of GPRC5D therapy in patients with multiple myeloma. The most common and only approved option is talquetamab-tgvs (Talvey). The panel highlighted the treatment in the phase 1/2 MonumenTAL-1 trial (NCT03399799; NCT04634552).

Using, Treating, and Sequencing GPRC5D Therapy

  • An important target because there needs to be a range of options developed to treat multiple myeloma.
    • This can be used prior to a B-cell maturation antigen (BCMA).
  • Can be considered to be used as a bridge to a BCMA or chimeric antigen receptor T-cell therapy.
  • GPRC5D is more commonly expressed in malignant plasma vs normal.
  • Combination therapies may produce higher efficacy rates than these monotherapies.
  • Talquetamab was assessed in the phase 1/2 MonumenTAL-3 trial (NCT05455320).
  • The most common toxicities include oral and skin.
    • Not as severe as with bispecific antibodies.
    • Hypothesized, as this is given one treatment at a time vs continuous bispecific use.
  • Dose de-escalation can be helpful to manage.
    • Monthly treatment may be an option to help lessen or avoid dysgeusia.
  • Talquetamab has not shown adverse effects (AEs) related to cardiac issues, pulmonary issues, renal issues, or neuropathy.
  • AEs typically happen at first onset and then lessen as the disease becomes better controlled.
  • As a GPRC5D target, there is less infectious toxicity involved.
    • Intravenous immunoglobulin supplementation is not needed as much.
Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
A panel of 5 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Related Content